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Neuronal nicotinic acetylcholine receptor (AChR) subtypes have been defined pharmacologically, immunologically, and by DNA cloning, but the 
correlations between these approaches are incomplete. Vertebrate neuronal AChRs that have been isolated are composed of structural subunits 
and ACh-binding subunits. A single kind of subunit can be used in more than one AChR subtype. Monoclonal antibody (mAb) 35 binds to structur- 
al subunits of subtypes of AChRs from both chicken brain and ganglia. By using antisera to a unique sequence of a3 ACh-binding subunits ex- 
pressed in bacteria, we show that ganglionic AChRs contain a3 ACh-binding subunits, whereas the brain AChR subtype that binds mAb 35 does 
not. Subunit-specific antisera raised against recombinant proteins should be a valuable approach for identifying the subunit composition of recep- 
tors in multigene, multisubunit families. 
Acetylchohne receptor, subtype; Antisera; Ganglion; Brain; Bacteria, expression in; Recombinant protein 
1. INTRODUCTION 
Subtypes of neuronal nicotinic acetylcholine recep- 
tors (AChRs) have been revealed by several indepen- 
dent methods. Ganglionic- and brain-type AChRs have 
been traditionally distinguished by pharmacological 
profiles [I]. Recently, more powerful methods have 
been used. Monoclonal antibodies (mAbs) raised 
against purified AChRs and cDNA clones permit far 
more detailed structural studies ([2-131; reviewed in 
[14,15]). These two complementary approaches show 
that nicotinic AChRs belong to the ligand-gated cation 
channel family, thus all are assumed to present in the 
same basic pattern of several subunits assembled 
around a central ion channel. The primary sequences of 
the subunits show well-conserved stretches of amino 
acids separated by less-conserved omains [5,12]. To 
date, at least seven [2-5,10-12,161 vertebrate genes con- 
sidered to code for neuronal nicotinic AChRs have been 
identified. The number of possible AChR subtypes ex- 
ceeds all previous expectations, thus requiring methods 
to associate genes with AChR subunits, and subunits 
with AChR subtypes identified by biochemical and 
pharmacological approaches. 
Previously, we reported the purification and 
characterization of two AChR subtypes from chicken 
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brains [6,7,17,18]. Together they account for > 90% of 
AChRs in chicken brains which bind nicotine with high 
affinity. One subtype corresponds to the single 
predominant subtype of AChR in mammalian brains 
which accounts for >90% of brain high-affinity 
nicotine binding sites [ 17,191. This subtype is composed 
of 75 kDa ACh-binding subunits encoded by a gene 
termed (~4 and by 49 kDa structural subunits termed p2 
-49kD Structural 
Subunit 
Fig. 1. mAb 35 binds to the ACh-binding subunit of Torpedo electric 
organ AChRs, but not to the structural subunit of chicken brain 
AChRs. Purified AChRs were resolved into their subunits by elec- 
trophoresis and the binding of mAb 35 was determined by Western 
blotting, as described in section 2. 
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or non-a, as demonstrated by N-terminal amino acid 
analysis of purified subunits [5,15,20]. The second sub- 
type of AChR purified from chicken brains is compos- 
ed of the same structural subunits, but different ACh- 
binding subunits, with molecular masses of 59 kDa, 
coded for by a gene yet to be determined [5,7]. These 
two chicken brain AChR subtypes can be further dif- 
ferentiated by the binding of mAb 35 which was raised 
to muscle-type AChRs from electric organs and binds 
to the main immunogenic region on the ACh-binding a 
subunits of muscle AChRs [Zl]. mAb 35 binds with 
high affinity to the AChR subtype with 59 kDa ACh- 
binding subunits, but with considerably lower affinity 
to the AChR subtype with 75 kDa subunits coded by cu4 
[6,7]. AChRs on chicken ciliary ganglia (CC) also avid- 
ly bind mAb 35 [22-241. These ganglionic AChRs differ 
from those in brain by their lower affinity for nicotine 
[I ,251 and higher affinity for neuronal bungarotoxin 
(Bgt) [24-261. 
Here we use antibodies to help determine the genes 
encoding the subunits of some of these AChR subtypes. 
mAb 35 is shown to bind to the structural subunits 
shared by several subtypes of neuronal AChRs. An- 
tiserum to a bacterially expressed, unique sequence of 
cr3 Ash-binding subunits is shown to bind AChRs of 
the subtype found in CG, but not to either of the 
predominant AChR subtypes in chicken brain. 
2. MATERIALS AND METHODS 
2.1. Western blot with mAb 35 
AChRs affinity purified from Torpedo electric organ on a toxin af- 
finity column (5 sg) [27f or immunoaffinity purified from chicken 
brain using mAb 295 [7] were electrophoresed on acrylamide gels in 
SDS, blotted as previously described [7], and probed overnight at 4°C 
with ‘Z51-mAb 35 (5 x 10’s cpm/mol, 1nM). After washing, binding of 
“sI-mAb 35 was visualized by autoradiography as previously describ- 
ed [7]. 
2.2. Subunit-specific antiserum 
Standard DNA cloning technology [28] was used to subclone the 
- 380 bp fragment obtained by a partial ff#rI/(complete) NcoI diges- 
tion of pCh35-1 into a pET3c-derived expression vector [29,30], 
yielding clone pCh35-4. Cloning sites were confirmed by DNA se- 
quencing. pCh35-1 is a partial cDNA clone (Whiting, P. et al., submit- 
ted) coding for a chicken ~y3 gene essentially identical to the genomic 
sequence published by Nef et al. [4]. The 380 bp HphI/Nco fragment 
codes for the peptide Leu315-Met441 (numbered as in [4]) and the 
deduced complete sequence of the recombinant protein protCh35-4 is: 
MASMTGGQQMGRIPLLNLLPRIMFMTRPTSDEENNOKPKPF- 
VKYIAENMK- 
YGLQEFEA (with a3 sequences under- 
lined). The additional amino acids are encoded by vector sequences. 
For expression, pCh35-4 was transformed into BL2l(DE3)pLysS. 
BLZl(DE3)pLysS is a variant of BL2l(DE3) [31] allowing better ex- 
pression of toxic genes (Rosenberg A., personal communication). 
Single colonies were grown to ODsss - 0.6-l .O in 50 ml 2 x YT, 100 
CM ampicillin and then induced with -0.5 mM isopropyl-,&D- 
thjog~actopyranoside (IPTG). The bacteria were harvested 2-3 h 
later by centr~fugation and the pellet resuspended in 50 mM Tris, 10 
mM EDTA, 0.5 mM PMSF, and subsequently l sed by freezing and 
thawing followed by 3 x 30 s sonication (Branson 200). After cen- 
trifugation for 20 min at 20000 rpm in a Ti50.2 rotor at 4°C. the 
recombinant protein was found in the pellet, indicating that it was in 
inclusion bodies. To remove impurities, this pellet was subsequently 
extracted first by vortexing with 15 ml of 50 mM Tris-HCl, pH 8.0, 
10 mM EDTA, 0.1 mM PMSF, 1% Triton; then with the same buf- 
fer, replacing Triton with 1 M NaCl; and finally replacing the NaCl 
with 3 M NaSCN. The resulting pellet containing protCh35-4 was 
dissolved in 10 ml of 8 M urea and 1 mM dithiothreitol (DTT) in 
phosphate-buffered saline (PBS), and then dialyzed against PBS, 1 
mM DTT, 5% cholate, containing urea in step-wise reduced concen- 
tration to zero. Rabbit antisera were obtained by subcutaneous im- 
munization with - 200 gg recombinant protein in complete Freund’s 
adjuvant over a period of 12 weeks. 
2.3. Binding of ‘251-mAb 35 and ‘2JI-&?gt 
Antiserum to the ~y3 peptide was tested for its ability to deplete bin- 
ding sites for mAb 35 and crBgt from detergent extracts of chick 
ciliary ganglia and brains. From embryonic day 17-19 (E18) chicks, 
40-50 CG or 0.5-0.6 g brains were homogenized in 1 ml or 10 ml, 
respectively, of 75 mM NaCl, 5 mM Na phosphate buffer, pH 7.4. 
Membranes were isolated by centrifugation at 15 000 x g for I5 min. 
The AChRs were solubihzed in 0.5 ml 5 mM NaP04/75 mM 
NaCl/l% Triton X-100, pH 7.4, and cleared from debris by 15 min 
(CC) or 30 min (brain) centrifugation at 15 000 x g. Aliquots were in- 
cubated with antisera or preimmune sera for 60 min at room 
temperature (RT) in a final volume of 60 ~1. Control reactions were 
carried out in the absence of sera. Then the antibodies were absorbed 
onto fixed Staph-A cells (BRL) (the pellet from 30~1 of a 10% suspen- 
sion) for an additional 15 min, and cleared by a 15 s centrifugation. 
Triplicate 30-~1 aliquots of supernate were incubated with 2.5 nM 
‘ZfI.mAb 35 for 45 min at RT. The amount of lz51-mAb 35 bound to 
AChR was determined by a DE-52 resin column assay (50~1 resin for 
CG, 150 pl for brain) as previously described [6,23]. In separate x- 
periments, triplicate 30-/t] aliquots of extracts were similarly labeled 
with 10 nM ‘%zBgt, and bound ‘%crBgt was measured using a 
microfiltration assay as previously described [23]. Non-specific 
binding was determined in the presence of a lOO-fold excess of 
unlabeled mAb 35 or cYBgt and was substracted from the total in all 
cases. 
2.4. ~HrNicotine binding 
Binding of [‘HInicotine to AChRs bound to antibodies was 
measured basically as previously described [17]. Triplicate 200~~1 ali- 
quots of Triton X-100 extracts of El8 chick brain were incubated at 
4°C overnight with lOpI diluted antisera and 30~1 goat anti-rat IgG- 
coupled Sepharose. The Sepharose pellet was washed twice with PBS, 
0.5% Triton by repeated centrifugation. The Sepharose-antibody- 
AChR complex was then incubated for 15 min in 20 nM [‘HInicotine 
at RT, followed by three rapid washes with PBS/O.S% Triton X-100 
at 4’C. Bound t3H]nicotine in the Sepharose pellet was measured by 
scintillation counting. 
395 
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3. RESULTS 
3.1. Identification of the AChR subunit recognized by 
mAb 3.5 
mAb 210, like mAb 35, binds to the main im- 
munogenic region on al subunits of muscle-type 
AChRs. Previously, we demonstrated that mAb 210 
binds to the structural subunits of both major subtypes 
of chicken brains AChRs [6,7]. mAb 210 has much 
higher affinity for native than denatured muscle-type 
AChRs, but binds specifically to the synthetic Torpedo 
electric organ AChR crl peptide a6876 (M. Das et al., 
unpublished), a sequence also recognized by several 
other mAbs to the main immunogenic region [32]. Like 
mAb 35, mAb 210 binds to the subtype of chicken brain 
AChR whose ACh-binding subunit has not been deter- 
mined [7], and it binds to AChRs from CG ([25]; 
Halvorsen, S. and Berg, D., submitted). The associa- 
tion of a4 ACh-binding subunits with structural 
subunits greatly reduces the affinity of mAb 210 for 
native chicken brain AChRs of the subtype with a4 
ACh-binding subunits [7]. 
mAb 35 is even more dependent on the native confor- 
mation of the main immunogenic region of AChRs 
than is mAb 210 [21,33]. Nonetheless, by using high 
specific activity ‘?-mAb 35 to label Western blots it 
was possible to demonstrate specific labeling of 
denatured subunits (fig.1). Like mAb 210, it labeled cul 
ACh-binding subunits of electric organ AChRs, but not 
structural subunits of neuronal AChRs. Thus, an an- 
tigenic feature of ACh-binding subunits of muscle-type 
AChRs is conserved in structural subunits of neuronal 
AChRs from some species. The demonstration that 
mAb 35 binds to ,&2 structural subunits used by several 
AChR subtypes may explain the ability of this mAb to 
bind to AChR subtypes that differ in their ACh-binding 
subunits. 
3.2. Expression of an ~3 fragment in bacteria 
The sequence between the hydrophobic segments M3 
and M4 of AChR subunit genes is highly variable in 
length and amino acid sequence (fig.2A). This sequence 
is known to be the cytoplasmic surface of electric organ 
AChR subunits [34,35], appears loosely organized by 
electron microscopy [31], and is recognized by many 
mAbs that bind to both native AChR and its denatured 
peptides [34,35]. Most subunit-specific mAbs bind in 
this region [34,35]. Therefore, the sequence between 
M3 and M4 was used for raising antibodies to the a3 
subunit. 
An a3-specific cDNA sequence encoding this 
putative cytoplasmic domain was cloned into a bacterial 
expression vector. Only induced bacterial cultures 
showed a predominant protein (protCh35-4) of ap- 
parent molecular mass of 18.8 kDa when analyzed on 
Coomassie-stained SDS-PAGE gels, which compares 
well with the calculated molecular mass of 17 kDa 
396 
(fig.2B). It was found that all of the induced 
protCh35-4 was present in inclusion bodies which pellet 
after centrifugation of the bacterial lysate. Subsequent 
extraction solubilized some contaminating proteins (not 
shown). After final solubilization of the inclusion 
bodies in urea plus DTT and low ‘renaturation’ through 
removal of urea by dialysis, most of protCh35-4 was 
still soluble. The resulting recombinant protein was 
> 90% pure as judged by SDS-PAGE (fig.2B). Approx- 
imately 15 mg of protCh35-4 was obtained from a 50 ml 
culture. 
3.3. Antisera to the CY~ peptide bind to AChRs from 
ganglia but not from brain 
Antisera raised to the purified bacterially expressed 
cr3 subunit peptide fragment were highly specific for the 
cr3 peptide as shown by Western blots in which only the 
cu3 peptide, but no other bacterial protein in a crude ex- 
tract, was heavily labeled with antibodies (fig.2B). 
,l . I 
” 
1 low4 13WO 1 loo0 1300 IIW 130 
Serum Ddution 
120 
B 
0 
13000 1 low 1300 1100 130 
Serum Dilution 
Fig.3. (A) Depletion of CG mAb 35 binding sites by antisera to the a3 
peptide. Chicken CG extracts (M) or brain extracts (C--O) 
were incubated with antisera to (~3 and fixed Staph A cells, then 
assayed for binding of “sI-mAb 35 as described in section 2. Substitu- 
tion of antiserum with preimmune sera at l/300 or l/30 dilutions 
resulted in no depletion of ‘*sI-mAb 35 binding sites. Values indicate 
the mean of two experiments + SE, except values at l/10 000, which 
are from a single experiment. (B) CG crBgt binding sites (U---U) are 
not recognized by antisera to the (~3 peptide. Experiments were car- 
ried out as in A, except that ‘2SI-~Bgt binding was measured. Values 
indicate the mean of two experiments f SE. 
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Fig.4 [3]Nicotine-labeled brain AChRs are not efficiently bound by antisera to the (~3 peptide. mAb 270 was used to determine total [‘HInicotine 
binding sites in the extract. Values are the mean of triplicate determinations + SE. 
Antisera to the cu3 peptide were tested for their ability 
to bind AChRs from chicken CG extracts and brain ex- 
tracts. AChRs in this assay were measured as mAb 35 
binding sites. Greater than 90% of CG AChRs were 
recognized by the antiserum, while no significant frac- 
tion of brain AChRs were (fig.3A). Thus, the ACh- 
binding subunit of CG AChRs is likely to be encoded by 
the cu3 gene, whereas the ACh-binding subunit of the 
brain AChR subtype bound by mAb 35 is not. 
Chicken brain AChRs that bind mAb 35 have high 
affinity for nicotine [17], whereas CG AChRs do not 
[24]. Antisera to the cu3 peptide were also tested for 
binding to brain high-affinity nicotinic binding sites. 
Antisera to a3 bound less than 7% of high-affinity 
nicotinic AChRs at antisera concentrations, which 
bound to virtually all CG AChRs (fig.4). These results 
using [3H]nicotine-labeled AChRs, together with those 
in fig.3 using 12?-mAb 35-labeled AChRs, indicate that 
AChR subtypes containing ~3 ACh-binding subunits: 
(i) probably do not have high affinity for nicotine; (ii) 
comprise the major AChR subtype in CG; and (iii) are 
a minor AChR subtype in brain. 
3.4. Antisera to the cu3 peptide do not bind to CG cuBgt- 
binding proteins (CuBgtBPs) 
In addition to nicotinic AChRs, aBgtBPs are found 
in CG [22,36]. Although neither their exact biochemical 
structure nor their function is known, they do bind ACh 
and are considered to be members of the ligand-gated 
ion channel family [37]. Antisera to the AChR cr3 pep- 
tide do not bind CG cuBgtBPs. 
4. DISCUSSION 
The growing number of genes considered to code for 
subunits of nicotinic AChRs requires methods to deter- 
mine the proteins encoded by the genes and to deter- 
mine which subunits comprise various AChR subtypes. 
Due to the multisubunit nature of AChRs, the complex- 
ity of this problem is significantly increased by the large 
number of possible permutations of different subunits 
in different subtypes. Identical problems exist for 
GABAA receptors and probably also for glycine recep- 
tors, which are also members of the ligand-gated ion 
channel superfamily [38-411. In some cases, it is possi- 
ble to purify enough protein to chemically determine 
partial amino acid sequences and thereby identify the 
cDNA clones encoding the subunits [5,20]. This might 
be the first approach for identifying a major receptor 
subtype, but it will be almost impossible for minor sub- 
types. Here, we took an alternative approach, starting 
from the available DNA sequences for a putative AChR 
subunit, by expressing a unique cu3 gene fragment in 
bacteria and then using antisera against the recombi- 
nant protein as a biochemical probe for the native 
AChR protein. In contrast to using chemically syn- 
thesized peptides as immunogens, recombinant proteins 
do not require chemical synthesis techniques or 
machines that may not be available in the laboratory, 
and they permit expression of relatively long peptides 
which are difficult to synthesize chemically and that are 
more likely to contain a desirable epitope. Recombinant 
proteins from the putative large cytoplasmic domain of 
subunits in the AChR gene family described here and 
elsewhere ([49], Schoepfer, R. et al., unpublished; 
Whiting, P. et al., submitted) have proven to be ex- 
cellent immunogens, having a significant fraction of an- 
tibodies that recognize native subunits. 
Others have used the Xenopus oocyte and other in 
vivo expression systems to address the problem of 
receptor subtypes [42-441. However, functional expres- 
sion of combinations of ligant-gated ion channel 
subunits, which are considered not to exist in vivo, can 
be obtained in in vitro expression systems [45,46]. 
397 
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Thus, the interpretation of data from in vitro systems 
has to be seen in context with biochemical data from in 
vivo systems. 
Here we show that mAb 35, like mAb 210 to the same 
epitope [6] and mAb 270 to another epitope [7], 
recognize structural subunits that are used by several 
AChR subtypes. mAbs 35 and 210 also recognize a 
putative structural subunit of CG AChRs (Halvorsen, 
S. and Berg, D., submitted). The type of ACh-binding 
subunit associated with the structural subunit may af- 
fect the ability of mAbs to bind to the structural 
subunit. The structural subunits used by the two promi- 
nent subtypes of AChRs from chicken brain are iden- 
tical by N-terminal sequence [5] and peptide maps [7], 
but antibodies to the highly conformation-dependent 
main immunogenic region, such as mAbs 35 and 210, 
do not bind with high affinity to native AChRs using a4 
ACh-binding subunits [7]. However, mAb 270, which 
binds to another epitope on the extracellular surface of 
AChR structural subunits, binds well to both AChR 
subtypes [7]. 
Here we show that antisera to a unique a3 peptide 
bind to CG AChRs. This provides strong evidence for 
an cu3-encoded subunit as part of CG AChRs. This is in 
agreement with the expression of high levels of cu3 
mRNA in CG, while no (r2 and very little a4 message is 
detectable [47]. Recently we have found that antisera to 
cu3 binds specifically to the ACh-binding subunits of 
AChRs purified from CG [S. Halvorsen and D. Berg, 
submitted]. 
We assume that the rat a3 gene encodes a rat 
ganglionic AChR as it is expressed in PC12 cells[lO]. 
We cannot test this with the antiserum described here, 
as the cytoplasmic loop used for obtaining the an- 
tiserum is not conserved between chicken and rat, while 
the rest of the gene is highly conserved. However, the 
(~3 gene is expressed in PC12 at high levels, and when 
expressed in oocytes in combination with ,&I structural 
subunits gives rise to AChRs which, like those in PC12 
cells, are blocked by neuronal Bgt [42]. Assuming that 
cu3 codes for AChRs on PC12 cells, our previous obser- 
vation [48] that the NGF-induced increase of AChRs on 
PC12 cells is not reflected by increased a3 mRNA 
amount can now only be interpreted to mean that under 
these conditions the amount of AChR on the surface of 
the cells does not increase in proportion to the amount 
of a3 mRNA. 
Because cu3 mRNA is also expressed in chicken brain 
in low levels [4,47, and P. Whiting et al., submitted], we 
also expect low levels of a3-encoded protein. This low 
level of a3-containing AChRs in brain might be too low 
to be detected by depletion of mAb 35 sites by antisera 
to the (~3 peptide (fig.3A). Alternatively, a3 in brain 
might be associated with a different subunit than in CG, 
and these may not bind mAb 35. But cu3 is not part of 
the brain AChR that binds mAb 35, has high affinity 
for nicotine, and is composed of a m-encoded struc- 
398 
tural subunit together with an as yet unidentified 59 
kDa ACh-binding subunit[5,7]. A likely candidate for 
the ACh-binding subunit of this AChR is a2 
(Schoepfer, R. et al., unpublished). The minimal bin- 
ding of antisera to cu3 to nicotine binding sites might 
reflect an as yet unidentified subtype, or the detection 
of low-affinity nicotine binding sites on a3 using 20 nM 
nicotine, or a minimal cross-reactivity to other subunits 
due to a few conserved amino acids with other genes. 
mAbs to the cu3 subunit (now being prepared) will serve 
as more specific probes for answering these questions. 
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